Work

Supplementary Data from Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Data from Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial

DOI: 10.1158/1078-0432.22482986

Authors: Jung-Min Lee, Richard G. Moore, Sharad Ghamande, Min S. Park, John P. Diaz, Julia Chapman, James Kendrick, Brian M. Slomovitz, Krishnansu S. Tewari, Elizabeth S. Lowe, Tsveta Milenkova, Sanjeev Kumar, Mike Dymond, Jessica Brown, Joyce F. Liu

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361814057

Cites: 1

Cited by:

Related to: 10